Pivotal trial to investigate aldoxorubicin in combination with Avastin in patients with relapsed glioblastoma

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 01 Dec 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aldoxorubicin (Primary) ; Bevacizumab (Primary)
Indications Glioblastoma
Focus Therapeutic Use

Most Recent Events

29 Jun 2015 New trial record
21 May 2015 According to a CytRx Corporation media release, the potential for this pivotal trial will be discussed at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight